Project Grant K08DK139369

Award Date 4/15/24
Completion Date 1/31/28
Dollars Obligated $472K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of complement activation in the development of sepsis-associated acute kidney injury (SA-AKI). The $571,107 award, effective July 22, 2024 through March 31, 2028, supports research conducted by the University of Colorado-Denver. The key objectives are to: 1)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop personalized sepsis therapeutics by integrating high-frequency physiologic data with electronic health record data. The $186,221 award, effective from February 1, 2025 to January 31, 2030, will support three primary research objectives: Augmenting sepsis phenotypes through the inclusion of high-frequency...
This federal Project Grant award, ID R41DK138646, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $548,830 award to Nephsmart LLC aims to develop and test a point-of-care device to predict the future development of severe acute kidney injury (AKI). The researchers have discovered that extensive cleavage of a specific protein occurs in the urine of...
This $1,218,750 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to improve sepsis care through the use of artificial intelligence (AI) and machine learning (ML) clinical decision support systems. The key products and services to be delivered under this 5-year award, which starts on July 15, 2024, include: Addressing critical knowledge gaps at the intersection of AI/ML methods and sepsis...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $455,000.00 to the Children's Research Institute to develop new therapeutic protocols for reducing sepsis mortality in pediatric populations. The key products and services to be delivered include: An AI-guided early identification tool for rapid sepsis detection, 2) Sepsis phenotyping and digital twin patient modeling to...
This $700,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s Immunix platform for precision medicine endotyping of sepsis patients. The project aims to: 1) validate Immunoscan immunoassays and generate mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the...
This National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) Project Grant award of $1,203,750 to Childrens Hospital Medical Center in Cincinnati, Ohio aims to advance the understanding of organ-specific microvascular endothelial responses in sepsis. The 5-year project from July 2024 to April 2029 will pursue three key objectives: 1) developing a transcriptomic atlas of circulating endothelial cells from children with septic shock to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to improve proteinuria testing and management after acute kidney injury (AKI). The $593,241 award, commencing on Jul 25, 2024, will fund a study led by Dr. Y. Diana Kwong, a nephrologist at the University of California, San Francisco (UCSF). The study will involve: 1) using semi-structured...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $2,378,837 in funding to the University of Massachusetts to develop novel nanopore- and click-chemistry-based approaches for accurate detection of sepsis-causing pathogens directly from blood samples. The goal is to create a rapid, user-friendly diagnostic device prototype that can identify sepsis-causing microorganisms within 2...
This Project Grant award, valued at $166,204.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) to The Medical College of Wisconsin, Inc. (MCW) for a five-year period from August 1, 2024 to July 31, 2028. The primary goal of this award is to support the development of Dr. Nicholas P. Semenkovich, a physician-scientist, to become an independent investigator focused on using cell-free DNA as a...

TRANSCRIPTOMIC DIAGNOSIS AND STAGING OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY - ACUTE KIDNEY INJURY IS DIAGNOSED IN OVER 50% OF PATIENTS WITH SEPSIS. SEPSIS-ASSOCIATED AKI (SAKI) CONTRIBUTES TO HIGH MORTALITY, THE DEVELOPMENT OF CHRONIC KIDNEY DISEASE (CKD) AND END- STAGE RENAL DISEASE (ESRD). DESPITE DECADES OF INVESTIGATION INTO THE PATHOPHYSIOLOGY AND TREATMENT OF SEPSIS AND ASSOCIATED KIDNEY INJURY, WE REMAIN WITHOUT DIAGNOSTIC TOOLS TO STRATIFY HUMAN AKI ETIOLOGY AND STAGE, WHICH WE SEEK TO ADDRESS IN THIS PROPOSAL. THE OVERALL GOAL OF OUR PROJECT IS TO TEST THE HYPOTHESIS THAT MURINE BLOOD TRANSCRIPTOMICS CAN BE USED TO DIAGNOSE AND STAGE HUMAN SAKI. WE WILL FIRST IDENTIFY MURINE BLOOD-BASED BIOMARKERS(MIRNA AND MRNA) REFLECTIVE OF SAKI TISSUE INJURY. WE WILL THEN USE THE MURINE BIOMARKERS TO STRATIFY HUMAN AKI ACCORDING TO SAKI DIAGNOSIS AND MOLECULAR STAGE. THE IMMEDIATE OUTCOME OF THIS WORK WILL BE THE DEVELOPMENT OF A LIQUID BIOPSY TO DIAGNOSE AND STAGE HUMAN SAKI. INDIANA UNIVERSITY HOUSES THE BIOBANK COHORT OF INDIANA AND IS AN ESTABLISHED TISSUE INTERROGATION SITE FOR THE KIDNEY PRECISION MEDICINE PROJECT (KPMP), THUS, MY INTERDISCIPLINARY MENTORING TEAM AND I ARE WELL-POSITIONED TO UNDERTAKE THIS HIGHLY TRANSLATABLE WORK. THE CURRENT PROPOSAL WILL DEVELOP A NUMBER OF SKILLS REQUIRED TO BE A SUCCESSFUL, INDEPENDENT TRANSLATIONAL RESEARCHER. WHILE MY LONG-TERM GOAL IS TREATMENT OF SAKI, THE IMPLEMENTATION OF THIS NECESSITATES SOLID BASIC SCIENCE AND COMPUTATIONAL SKILL SETS. THIS WILL ALLOW FOR FUTURE WORK FOCUSED ON THE TREATMENT OF SAKI. IF THESE STUDIES SHOW EFFICACY IN THE DIAGNOSIS AND STAGING OF HUMAN AKI, THESE STRATEGIES MAY BE RAPIDLY TRANSLATED INTO THE CLINICAL SETTING.

Posted 4/5/24, 12:00 AM